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gender is attributable to the presence of concomitant clinical comor-
bidities. The adjusted effect of gender on outcomes was uniform be-
tween clinical presentations.
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BACKGROUND There is limited information of clinical outcomes after
chronic total occlusion (CTO) revascularization by drug-eluting stent
(DES) compared to coronary artery bypass grafting (CABG). We per-
formed the long-term (5-year) follow-up of patients who underwent
percutaneous coronary intervention (PCI) using DES or CABG for CTO
revascularization.
METHODS We identiﬁed 883 patients with CTO who underwent PCI
using DES (n¼484) or CABG (n¼399) in Asan Medical Center between
January 2005 and May 2010. The primary end point was a major
adverse cardiac event (MACE), which was composite of death from
any cause, myocardial infarction or target vessel revascularization.
RESULTS After adjustment for difference in baseline characteristics,
the 5-year incidence of MACE was similar between two groups (hazard
ratio [HR]:0.80; 95% conﬁdence interval [CI]: 0.51-1.27, p¼0.35). In
addition, individual component of the primary endpoint, including
death (HR: 0.67; 95% CI: 0.40-1.14, p¼0.14), myocardial infarction
(HR: 0.57; 95% CI: 0.11-2.99, p¼0.51), and target vessel revasculari-
zation (HR: 1.43; 95% CI: 0.47-4.37, p¼0.53) were not signiﬁcantly
different between two groups. However, the risk of new lesion
revascularization was signiﬁcantly higher (HR: 19.79; 95% CI: 2.04 –
192.37, p¼0.01) and risk of cerebrovascular event was lower (HR: 0.12;
95% CI: 0.02-0.7, p¼0.02) in the DES group.
Table 1. Adjusted Hazard Ratio for Clinical Outcomes at 5 Year After PCI using DES as Compared With After
CABG in the Overall PopulationClinical outcomes Adjusted HR (95% CI) P valueMACEy 0.80 (0.51 – 1.27) 0.35
Death 0.67 (0.40 – 1.14) 0.14Cardiac Death 0.56 (0.30 – 1.06) 0.08Myocardial Infarction 0.57 (0.11 – 2.99) 0.51Death or MI 0.70 (0.42 – 1.15) 0.16Repeat RevascularizationTarget Vessel Revascularization 1.43 (0.47 – 4.37) 0.53CTO Vessel Revascularization 3.41 (0.60 – 19.33) 0.17New Lesion Revascularization 19.79 (2.04 – 192.37) 0.01Cerebrovascular Event 0.12 (0.02 – 0.7) 0.02Major Bleeding 0.57 (0.22 – 1.48) 0.24yThe composite of death from any causes, myocardial infarction and target vessel revascularizationCONCLUSIONS For patients with CTO, DES treatment, compared with
CABG, showed similar rates of mortality and the combined end point
of MACE up to 5 years.
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BACKGROUND Dual antiplatelet therapy (DAPT) prevents myocardial
infarction (MI), yet increases bleeding complications after percuta-
neous coronary intervention (PCI). Whether or not the mortality risks
after each type of adverse event are comparable, both in magnitude
and over time, to one another is unclear.
METHODS We examined associations between MI, bleeding requiring
hospitalization (BRH) and one-year mortality in the PROMETHEUS
cohort, a multicenter observational study (n¼19,914) of acute coro-
nary syndrome (ACS) patients treated with PCI. Hazard ratios for MI
and BRH were generated using Cox regression with each adverse
event entered as a time-updated covariate.
RESULTS One-year rates of all-cause mortality, MI and BRH were
5.6% (n¼963), 5.5% (n¼977) and 4.4% (n¼776), respectively. Patients
with BRH were older, more often female with a higher frequency of
renal dysfunction compared to those with MI. In contrast, diabetes
mellitus, current smoking and prior PCI were more commonly
observed in those with MI. Adjusted HRs for mortality associated with
MI and BRH were 2.3 (95% CI 1.9-2.8) and 2.3 (95% CI 1.8-2.8),
respectively. Mortality risk was highest up to 30 days after either
event, and remained signiﬁcantly increased, albeit attenuated,
beyond 30 days post event (Figure).
B200 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5CONCLUSIONS MI and BRH are associated with comparable and du-
rable mortality risks over one year in ACS patients undergoing PCI.
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BACKGROUND There is no consensus regarding the duration of stent
inﬂation to achieve optimal stent expansion. We have devised a novel
inﬂation protocol named ”pressure optimization protocol (“POP”) that
uses pressure stabilization for at least 30 seconds at peak inﬂation
pressure as an endpoint. We have previously shown by OCT that POP
improves stent expansion vs rapid inﬂation/deﬂation, is safe, and
requires approximately 100 seconds to achieve pressure stability. To
determine whether POP is safe in long-term follow-up, we determined
target vessel failure (TVF¼composite of target vessel revasculariza-
tion, myocardial infarction and cardiac death) in our single-center
cohort and compared it to a contemporaneously treated group who
underwent a rapid inﬂation/deﬂation deployment technique.
METHODS 736 patients who underwent PCI using either routine stent
inﬂation (non-POP, n¼320) or POP (n¼416) between Jan 2009- March
2014 were included. Baseline clinical, lesion and PCI characteristics
were recorded. The primary endpoint was target vessel failure.
RESULTS Mean inﬂation time in POP group was signiﬁcantly longer
than rapid inﬂation/deﬂation group (104þ 45 s vs. 19 þ17 s, p <0.001).
At a mean follow-up duration of 1211 days (range 0- 2191) cumulative
survival free from TVF (Figure) was signiﬁcantly better in the POP
group compared to the rapid inﬂation/deﬂation group(89.9% vs
82.5%; log rank chi2 ¼ 18.7; p<0.0001).CONCLUSIONS Prolonged stent inﬂation using pressure optimization
appears to improve long-term outcomes after stent implantation in
our center. This retrospective quality improvement analysis needs to
be conﬁrmed in a randomized controlled trial.
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BACKGROUND Heart failure (HF) is the major cause of death in cardio-
vascular disease. In a post-STICH environment, we lack data on the role of
PCI in systolic HF patients. Complete revascularization of myocardium
remains one of the key unanswered questions in ischemic HF.
METHODS The COMMIT-HF is an ongoing single-center systolic HF
registry (inclusion criteria: HF with LVEF <35%, exclusion: ACS). A
total of 1798 patients were enrolled since 2009. Among them we have
selected a group of patients with multivessel CAD qualiﬁed for PCI.
The subjects were divided into complete (n¼188) and incomplete
revascularization (n¼159) groups. Completeness of revascularization
was deﬁned as successful PCI of every angiographically signiﬁcant
lesion in all arteries with a diameter of 2mm without a patent surgical
graft. All of the analyzed patients are followed up for a period of at
least 12 months with all-cause mortality deﬁned as primary endpoint.
RESULTS Patient characteristics are presented in table 1. Both groups
showed no signiﬁcant differences in clinical status and echocardiographic
parameters, however therewas a higher comorbidity rate in the incomplete
revascularization group. Drug-eluting stents were implanted more
frequently in the complete revascularization group (65,9% vs. 52,8%,
p¼0,01), with no other signiﬁcant differences in PCI strategy with very low
and comparable complication rates. All-cause mortality was signiﬁcantly
higher in the incomplete revascularizationgroupboth after 12-month (6,4%
vs 20,1%, p<0,001) and 24-month (14,2% vs 27,2%, p¼0,004) follow-up
period. In multivariate analysis complete revascularization was an inde-
pendent factor improving survival (OR 0,33, 95% CI 0,14-0,74, p¼0,007).Complete
revascularizationIncomplete
revascularization pSex 157M vs 31F 130M vs 29F 0,66Age 63,710,6 66,511,2 0,01
Mean EF [%] 28,55,6 27,35,4 0,13
NYHA III & IV [%] 40,9 49,0 0,13Prior PCI [%] 76,6 47,8 <0,01Prior CABG [%] 24,6 22,5 0,68ICD/CRT-D [%] 51,8 53,4 0,76Atrial ﬁbrillation [%] 23,4 26,4 0,51Anemia [%] 37,7 37,7 0,99Chronic kidney disease stage III-V [%] 23,9 33,9 0,04Diabetes mellitus [%] 42,0 54,1 0,02CONCLUSIONS Our observational study shows, that in an unselected
ischemic HF population angiographically-driven complete percuta-
neous revascularization has led to improved 12 and 24-month sur-
vival. If possible, complete revascularization in ischemic HF should
always be considered and is a deﬁnite candidate for further random-
ized studies.
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BACKGROUND The use of multiple geographical sites for randomized
cardiovascular trials may sometimes lead to important heterogeneity
